


Neurotech International Revenue
Biotechnology Research • 145 Stirling Highway, Suite 5 CPC, Australia • 1-10 Employees
Neurotech International revenue & valuation
| Annual revenue | $155,237 |
| Revenue per employee | $18,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $496,758 |
| Total funding | No funding |
Key Contacts at Neurotech International
Gerald Quigley
Non Executive Director
Anthony Filippis
Managing Director And Chief Executive Officer
Company overview
| Headquarters | 145 Stirling Highway, Suite 5 CPC, Nedlands, WA 6009, AU |
| Phone number | +611719383580 |
| Website | |
| NAICS | 541714 |
| SIC | 384 |
| Keywords | Autism, Clinical Research, Product Development, Drug Development, Medical Research, Biomedical R&D, Medical Innovation, Paediatric Neurology, Autism Spectum Disorder |
| Founded | 2016 |
| Employees | 1-10 |
| Socials |
Neurotech International Email Formats
Neurotech International uses 1 email format. The most common is {2char} (e.g., {2char}@neurotechinternational.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{2char} | {2char}@neurotechinternational.com | 100% |
About Neurotech International
Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated safety and efficacy results at 28 days, 20 weeks and 32 weeks of daily treatment with NTI164. The Company commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. The Company will also be conducting additional Phase I/II trial in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with a Phase I/II trial in Cerebral Palsy during CY2023. Additionally, Neurotech is commercialising Mente, the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech please visit http://www.neurotechinternational.com
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Neurotech International has 6 employees across 6 departments.
Departments
Number of employees
Funding Data
Neurotech International has never raised funding before.
Neurotech International Tech Stack
Discover the technologies and tools that power Neurotech International's digital infrastructure, from frameworks to analytics platforms.
Form builders
JavaScript graphics
JavaScript libraries
JavaScript libraries
CDN
WordPress themes
JavaScript libraries
Programming languages
Blogs
Analytics
Video players
Frequently asked questions
4.8
40,000 users



